Polaryx Therapeutics Receives FDA Orphan Drug Designation for PLX-200 to Treat Krabbe Disease
02 sept. 2021 00h00 HE
|
Polaryx Therapeutics, Inc
PARAMUS, N.J., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. ("Polaryx"), a biotech company developing small molecule therapeutics for lysosomal storage disorders, announced today...